Cipla’s wholly-owned subsidiary, Goldencross Pharma Private Ltd, on Monday, signed an agreement to acquire 11.71 per cent stake in Wellthy Therapeutics Private Ltd for ₹10.5 crore. The transaction is expected to be completed by March 10. Cipla and Wellthy have entered into a partnership to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.